Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, Third Edition, is the only pocket-sized, quick reference for pathology and transfusion medicine residents and fellows. It covers all topics in transfusion medicine and clinical and laboratory-based coagulation. Chapters are organized by multiple hierarchical headings and are supplemented with up to 10 suggested reading citations. This single handbook covers all the topics required to meet the goals of a major program in transfusion medicine and clinical coagulation. Changes to this edition include the latest AABB standards and new chapters focused on a wider range of specific populations requiring blood and related products.
Coverage includes essential updates on peripheral blood and bone marrow hematopoietic progenitor cells, as well as cord blood banking and regenerative medicine. The authors also examine advances in therapeutic apheresis and new cellular therapies.
1. Chapter 1. Introduction to Blood Banking and Transfusion Medicine - p. 3 2. Chapter 2. Quality Principles in Transfusion Medicine - p. 7 3. Chapter 3. Regulatory Issues in Transfusion Medicine - p. 17 4. Section 1 - p. 25 5. Blood Banking - p. 25 6. Chapter 4. Role of the Physician in the Blood Center - p. 27 7. Section 2 - p. 30 8. Donation Process - p. 30 9. Chapter 5. Blood Donation - p. 31 10. Chapter 6. Apheresis Blood Component Collections - p. 39 11. Chapter 7. Recipient-Specific Blood Donation - p. 43 12. Chapter 8. Adverse Donor Reactions - p. 47 13. Section 3 - p. 51 14. Component Manufacturing - p. 51 15. Chapter 9. Component Preparation and Manufacturing - p. 53 16. Section 4 - p. 58 17. Donor Testing - p. 58 18. Chapter 10. Serologic Testing of Donor Products - p. 59 19. Chapter 11. Overview of Infectious Disease Testing - p. 63 20. Chapter 12. Human Immunodeficiency Virus Screening - p. 69 21. Chapter 13. Hepatitis B Virus Screening - p. 73 22. Chapter 14. Hepatitis C Virus Screening - p. 77 23. Chapter 15. West Nile Virus Screening - p. 79 24. Chapter 16. Zika Virus Screening - p. 83 25. Chapter 17. Babesia Screening - p. 87 26. Chapter 18. Syphilis, Human T-Cell Lymphotropic Virus, and Chagas Screening - p. 91 27. Chapter 19. Bacterial Screening - p. 97 28. Section 5 - p. 100 29. Transfusion Medicine - p. 100 30. Chapter 20. Role of the Transfusion Service Physician - p. 101 31. Section 6 - p. 105 32. Testing - p. 105 33. Chapter 21. Pretransfusion Testing - p. 107 34. Chapter 22. Antibody Identification - p. 117 35. Chapter 23. Direct Antiglobulin Test - p. 127 36. Chapter 24. Molecular DNA–Based Blood Group Typing - p. 131 37. Section 7 - p. 137 38. Antigens - p. 137 39. Chapter 25. ABO and H Blood Group System - p. 139 40. Chapter 26. Rh and RhAG Blood Group Systems - p. 149 41. Chapter 27. Kell, Kx and Kidd Blood Group Systems - p. 157 42. Chapter 28. MNS and Duffy Blood Group Systems - p. 163 43. Chapter 29. Lewis, I, P1PK, FORS, and GLOB Blood Group Systems - p. 169 44. Chapter 30. Other Blood Group Systems, Collections, and Series - p. 177 45. Chapter 31. Human Platelet Antigens - p. 185 46. Section 8 - p. 189 47. Blood Products - p. 189 48. Chapter 32. Human Leukocyte Antigens - p. 191 49. Chapter 33. Red Blood Cells Products - p. 199 50. Chapter 34. Plasma Products - p. 205 51. Chapter 35. Platelet Products - p. 213 52. Chapter 36. Cryoprecipitate and Fibrinogen Concentrates - p. 219 53. Chapter 37. Granulocyte Products - p. 225 54. Chapter 38. Albumin and Related Products - p. 229 55. Chapter 39. Human Immunoglobulin Preparations - p. 235 56. Chapter 40. Rh Immune Globulin - p. 247 57. Chapter 41. Coagulation Factor Products - p. 251 58. Section 9 - p. 260 59. Product Modifications - p. 260 60. Chapter 42. Irradiation of Blood Products - p. 261 61. Chapter 43. Leukoreduction of Blood Products - p. 267 62. Chapter 44. CMV-Safe Blood Products - p. 271 63. Chapter 45. Frozen Blood Products - p. 277 64. Chapter 46. Washed Blood Products - p. 281 65. Chapter 47. Volume-Reduced Blood Products - p. 285 66. Chapter 48. Pathogen Reduction Technologies - p. 289 67. Section 10 - p. 293 68. Specific Clinical Settings - p. 293 69. Chapter 49. Neonatal and Pediatric Transfusion Medicine - p. 295 70. Chapter 50. Perinatal Transfusion Medicine - p. 301 71. Chapter 51. Autoimmune Hemolytic Anemias - p. 313 72. Chapter 52. Transfusion Management of Patients With Sickle Cell Disease and Thalassemia - p. 325 73. Chapter 53. Transfusion Management of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation - p. 337 74. Chapter 54. Transfusion Management of Patients Receiving Antithrombotic Therapy - p. 343 75. Chapter 55. Blood Transfusion in Economically Restricted and Developing Countries - p. 351 76. Chapter 56. Management of Patients Who Refuse Blood Transfusion - p. 357 77. Chapter 57. Platelet Transfusion Refractory Patients - p. 361 78. Chapter 58. Massive Transfusion - p. 365 79. Chapter 59. Patient Blood Management - p. 371 80. Section 11 - p. 378 81. Transfusion Reactions - p. 378 82. Chapter 60. Overview of Adverse Events and Outcomes After Transfusion - p. 379 83. Chapter 61. Febrile Nonhemolytic Transfusion Reactions - p. 385 84. Chapter 62. Allergic Transfusion Reactions - p. 389 85. Chapter 63. Acute Hemolytic Transfusion Reactions - p. 393 86. Chapter 64. Delayed Hemolytic Transfusion Reactions - p. 397 87. Chapter 65. Transfusion-Associated Circulatory Overload - p. 401 88. Chapter 66. Transfusion-Related Acute Lung Injury - p. 405 89. Chapter 67. Septic Transfusion Reactions - p. 409 90. Chapter 68. Metabolic, Hypotensive, and Other Acute Reactions and Complications - p. 413 91. Chapter 69. Posttransfusion Purpura - p. 419 92. Chapter 70. Transfusion-Associated Graft-Versus-Host Disease - p. 423 93. Chapter 71. Transfusion-Related Immunomodulation - p. 429 94. Chapter 72. Iron Overload - p. 433 95. Chapter 73. Transfusion-Transmitted Diseases - p. 437 96. Section 12 - p. 452 97. Therapeutic Apheresis and Phlebotomy - p. 452 98. Chapter 74. Overview of Therapeutic Apheresis - p. 455 99. Chapter 75. Therapeutic Plasma Exchange - p. 469 100. Chapter 76. Therapeutic Erythrocytapheresis and Red Cell Exchange - p. 477 101. Chapter 77. Therapeutic Thrombocytapheresis - p. 481 102. Chapter 78. Therapeutic Leukocytapheresis and Adsorptive Cytapheresis - p. 483 103. Chapter 79. Extracorporeal Photopheresis - p. 487 104. Chapter 80. LDL Apheresis - p. 493 105. Chapter 81. Immunoadsorption - p. 497 106. Chapter 82. Therapeutic Phlebotomy - p. 501 107. Section 13 - p. 503 108. Cellular Therapy, Regenerative Medicine, and Tissue Banking - p. 503 109. Chapter 83. Overview of Cellular Therapy - p. 505 110. Chapter 84. Hematopoietic Progenitor Cell Products Derived From Bone Marrow and Peripheral Blood - p. 513 111. Chapter 85. Cord Blood Banking - p. 519 112. Chapter 86. Regenerative Medicine - p. 527 113. Chapter 87. T-Cell Immune Therapies - p. 533 114. Chapter 88. Adverse Events Associated With Hematopoietic Progenitor Cell Product Infusion - p. 537 115. Chapter 89. Quality and Regulatory Issues in Cellular Therapy - p. 543 116. Chapter 90. Tissue Banking in the Hospital Setting - p. 553 117. PART II: Hemostasis - p. 554 118. Chapter 91. Overview of the Coagulation System - p. 559 119. Section 14 - p. 564 120. Clinical Coagulation - p. 564 121. Chapter 92. Approach to the Pediatric Patient With a Bleeding Disorder - p. 565 122. Section 15 - p. 570 123. Neonatal Thrombocytopenia - p. 570 124. Chapter 93. Congenital Thrombocytopenia - p. 571 125. Chapter 94. Fetal and Neonatal Alloimmune Thrombocytopenia - p. 581 126. Chapter 95. Acquired Neonatal Thrombocytopenia - p. 589 127. Section 16 - p. 593 128. Inherited Platelet Function Disorders - p. 593 129. Chapter 96. Bernard–Soulier Syndrome and Other GPIb-IX-Related Receptor Defects - p. 595 130. Chapter 97. Glanzmann Thrombasthenia - p. 599 131. Chapter 98. Platelet Storage Granule Defects - p. 601 132. Chapter 99. Failure to Release and Aspirin-Like Defects - p. 605 133. Chapter 100. Other Platelet Abnormalities - p. 609 134. Section 17 - p. 610 135. Immune Thrombocytopenia - p. 610 136. Chapter 101. Acute (Childhood) Immune Thrombocytopenia - p. 613 137. Chapter 102. Chronic Immune Thrombocytopenia - p. 619 138. Chapter 103. Drug-Induced Thrombocytopenia - p. 623 139. Chapter 104. Heparin-Induced Thrombocytopenia - p. 627 140. Chapter 105. Autoimmune Lymphoproliferative Syndrome - p. 641 141. Section 18 - p. 644 142. Immune Mediated Coagulopathies - p. 644 143. Chapter 106. Hemolytic Uremic Syndrome - p. 645 144. Chapter 107. Thrombotic Thrombocytopenic Purpura - p. 649 145. Chapter 108. Antiphospholipid Syndrome - p. 655 146. Section 19 - p. 666 147. Congenital Bleeding Disorders - p. 666 148. Chapter 109. von Willebrand Disease - p. 669 149. Chapter 110. Hemophilia A - p. 677 150. Chapter 111. Hemophilia B - p. 685 151. Chapter 112. Factor XI Deficiency - p. 691 152. Chapter 113. Factor VII Deficiency - p. 695 153. Chapter 114. Factor II, Factor V, and Factor X Deficiencies - p. 699 154. Chapter 115. Congenital Disorders of Fibrinogen - p. 703 155. Factor XIII, α2-Antiplasmin, and Plasminogen Activator Inhibitor-1 Deficiencies - p. 707 156. Section 20 - p. 710 157. Acquired Bleeding Disorders - p. 710 158. Chapter 117. Bleeding Disorders in Pregnancy - p. 711 159. Chapter 118. Vascular Bleeding Disorders - p. 719 160. Chapter 119. Hemostasis in Liver Disease - p. 723 161. Chapter 120. Bleeding Risks With Vitamin K Deficiency - p. 729 162. Chapter 121. Bleeding Risks With Cardiac Disease - p. 735 163. Chapter 122. Bleeding Risks With Renal Disease - p. 739 164. Chapter 123. Bleeding Risks With Cancer - p. 743 165. Chapter 124. Disseminated Intravascular Coagulopathy - p. 749 166. Chapter 125. Coagulopathy in Sickle Cell Disease - p. 757 167. Chapter 126. Acquired Coagulation Factor Inhibitors - p. 761 168. Section 21 - p. 766 169. Laboratory Testing of Coagulation - p. 766 170. Chapter 127. Overview of Purposes of Hemostasis Testing and Common Sources of Error - p. 767 171. Section 22 - p. 772 172. Screening Tests - p. 772 173. Chapter 128. Prothrombin Time - p. 773 174. Chapter 129. Activated Partial Thromboplastin Time - p. 779 175. Section 23 - p. 781 176. Laboratory Assessment of Coagulation Disorders - p. 781 177. Chapter 130. Mixing Studies - p. 783 178. Chapter 131. Coagulation Factor Testing - p. 785 179. Chapter 132. Specific Factor Inhibitor Testing - p. 789 180. Chapter 133. Thrombin Time and Fibrinogen Evaluation - p. 793 181. Chapter 134. Laboratory Diagnosis of Inherited von Willebrand Disease - p. 799 182. Chapter 135. Laboratory Diagnosis of Acquired von Willebrand’s Syndrome - p. 807 183. Chapter 136. Laboratory Assessment of Treatment of von Willebrand Disease - p. 809 184. Chapter 137. Measurement of Platelet Count, Mean Platelet Volume, and Reticulated Platelets - p. 811 185. Chapter 138. Platelet Function Analyzer - p. 817 186. Chapter 139. Thromboelastography/Thromboelastometry - p. 819 187. Chapter 140. Platelet Aggregation Studies - p. 827 188. Chapter 141. Laboratory Diagnosis of Platelet Functional Defects - p. 833 189. Chapter 142. Confirmatory Testing for Diagnosis of Platelet Disorders - p. 841 190. Chapter 143. Antiplatelet Therapy Monitoring - p. 849 191. Chapter 144. Laboratory Evaluation of Factor XIII Deficiency - p. 855 192. Chapter 145. Fibrinolytic Testing - p. 861 193. Chapter 146. Laboratory Techniques in Fibrinolysis Testing - p. 865 194. Section 24 - p. 867 195. Tests for Hypercoagulable State - p. 867 196. Chapter 147. Laboratory Evaluation of Long-Term Thrombophilic Disorders - p. 869 197. Chapter 148. Thrombophilia Testing in the Pediatric Population - p. 875 198. Chapter 149. Antithrombin Testing - p. 881 199. Chapter 150. Protein C Deficiency Evaluation - p. 887 200. Chapter 151. Protein S Deficiency Evaluation - p. 893 201. Chapter 152. Testing for Activated Protein C Resistance - p. 899 202. Chapter 153. Molecular Testing for Factor V Leiden and Prothrombin Gene Mutations in Inherited Thrombophilia - p. 903 203. Chapter 154. Chronic Elevated Levels of Factor VIII and Other Coagulation Factors - p. 907 204. Chapter 155. Acquired Prothrombotic Conditions - p. 909 205. Chapter 156. Laboratory Evaluation of Heparin-Induced Thrombocytopenia - p. 913 206. Chapter 157. Laboratory Evaluation of Thrombotic Thrombocytopenic Purpura - p. 919 207. Chapter 158. Laboratory Diagnosis of Lupus Anticoagulant and Antiphospholipid Antibodies - p. 925 208. Section 25 - p. 931 209. Laboratory Support of Anticoagulation - p. 931 210. Chapter 159. Laboratory Monitoring for Heparins, Fondaparinux, Direct Thrombin Inhibitors, and Oral Anti-Xa Medications - p. 933 211. Chapter 160. Laboratory Support for Warfarin Monitoring - p. 939 212. Section 26 - p. 943 213. Emerging topics in hemostasis testing - p. 943 214. Chapter 161. Molecular Testing in Coagulation - p. 945 215. Chapter 162. Circulating Microparticles - p. 955 216. Chapter 163. Thrombin Generation Assays - p. 965 217. Chapter 164. Diagnostic Use of Venoms - p. 969 218. Abbreviations - p. 977 219. Index - p. 983
Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, Third Edition, is the only pocket-sized, quick reference for pathology and transfusion medicine residents and fellows. It covers all topics in transfusion medicine and clinical and laboratory-based coagulation. Chapters are organized by multiple hierarchical headings and are supplemented with up to 10 suggested reading citations. This single handbook covers all the topics required to meet the goals of a major program in transfusion medicine and clinical coagulation. Changes to this edition include the latest AABB standards and new chapters focused on a wider range of specific populations requiring blood and related products.
Coverage includes essential updates on peripheral blood and bone marrow hematopoietic progenitor cells, as well as cord blood banking and regenerative medicine. The authors also examine advances in therapeutic apheresis and new cellular therapies.
1. Chapter 1. Introduction to Blood Banking and Transfusion Medicine - p. 3 2. Chapter 2. Quality Principles in Transfusion Medicine - p. 7 3. Chapter 3. Regulatory Issues in Transfusion Medicine - p. 17 4. Section 1 - p. 25 5. Blood Banking - p. 25 6. Chapter 4. Role of the Physician in the Blood Center - p. 27 7. Section 2 - p. 30 8. Donation Process - p. 30 9. Chapter 5. Blood Donation - p. 31 10. Chapter 6. Apheresis Blood Component Collections - p. 39 11. Chapter 7. Recipient-Specific Blood Donation - p. 43 12. Chapter 8. Adverse Donor Reactions - p. 47 13. Section 3 - p. 51 14. Component Manufacturing - p. 51 15. Chapter 9. Component Preparation and Manufacturing - p. 53 16. Section 4 - p. 58 17. Donor Testing - p. 58 18. Chapter 10. Serologic Testing of Donor Products - p. 59 19. Chapter 11. Overview of Infectious Disease Testing - p. 63 20. Chapter 12. Human Immunodeficiency Virus Screening - p. 69 21. Chapter 13. Hepatitis B Virus Screening - p. 73 22. Chapter 14. Hepatitis C Virus Screening - p. 77 23. Chapter 15. West Nile Virus Screening - p. 79 24. Chapter 16. Zika Virus Screening - p. 83 25. Chapter 17. Babesia Screening - p. 87 26. Chapter 18. Syphilis, Human T-Cell Lymphotropic Virus, and Chagas Screening - p. 91 27. Chapter 19. Bacterial Screening - p. 97 28. Section 5 - p. 100 29. Transfusion Medicine - p. 100 30. Chapter 20. Role of the Transfusion Service Physician - p. 101 31. Section 6 - p. 105 32. Testing - p. 105 33. Chapter 21. Pretransfusion Testing - p. 107 34. Chapter 22. Antibody Identification - p. 117 35. Chapter 23. Direct Antiglobulin Test - p. 127 36. Chapter 24. Molecular DNA–Based Blood Group Typing - p. 131 37. Section 7 - p. 137 38. Antigens - p. 137 39. Chapter 25. ABO and H Blood Group System - p. 139 40. Chapter 26. Rh and RhAG Blood Group Systems - p. 149 41. Chapter 27. Kell, Kx and Kidd Blood Group Systems - p. 157 42. Chapter 28. MNS and Duffy Blood Group Systems - p. 163 43. Chapter 29. Lewis, I, P1PK, FORS, and GLOB Blood Group Systems - p. 169 44. Chapter 30. Other Blood Group Systems, Collections, and Series - p. 177 45. Chapter 31. Human Platelet Antigens - p. 185 46. Section 8 - p. 189 47. Blood Products - p. 189 48. Chapter 32. Human Leukocyte Antigens - p. 191 49. Chapter 33. Red Blood Cells Products - p. 199 50. Chapter 34. Plasma Products - p. 205 51. Chapter 35. Platelet Products - p. 213 52. Chapter 36. Cryoprecipitate and Fibrinogen Concentrates - p. 219 53. Chapter 37. Granulocyte Products - p. 225 54. Chapter 38. Albumin and Related Products - p. 229 55. Chapter 39. Human Immunoglobulin Preparations - p. 235 56. Chapter 40. Rh Immune Globulin - p. 247 57. Chapter 41. Coagulation Factor Products - p. 251 58. Section 9 - p. 260 59. Product Modifications - p. 260 60. Chapter 42. Irradiation of Blood Products - p. 261 61. Chapter 43. Leukoreduction of Blood Products - p. 267 62. Chapter 44. CMV-Safe Blood Products - p. 271 63. Chapter 45. Frozen Blood Products - p. 277 64. Chapter 46. Washed Blood Products - p. 281 65. Chapter 47. Volume-Reduced Blood Products - p. 285 66. Chapter 48. Pathogen Reduction Technologies - p. 289 67. Section 10 - p. 293 68. Specific Clinical Settings - p. 293 69. Chapter 49. Neonatal and Pediatric Transfusion Medicine - p. 295 70. Chapter 50. Perinatal Transfusion Medicine - p. 301 71. Chapter 51. Autoimmune Hemolytic Anemias - p. 313 72. Chapter 52. Transfusion Management of Patients With Sickle Cell Disease and Thalassemia - p. 325 73. Chapter 53. Transfusion Management of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation - p. 337 74. Chapter 54. Transfusion Management of Patients Receiving Antithrombotic Therapy - p. 343 75. Chapter 55. Blood Transfusion in Economically Restricted and Developing Countries - p. 351 76. Chapter 56. Management of Patients Who Refuse Blood Transfusion - p. 357 77. Chapter 57. Platelet Transfusion Refractory Patients - p. 361 78. Chapter 58. Massive Transfusion - p. 365 79. Chapter 59. Patient Blood Management - p. 371 80. Section 11 - p. 378 81. Transfusion Reactions - p. 378 82. Chapter 60. Overview of Adverse Events and Outcomes After Transfusion - p. 379 83. Chapter 61. Febrile Nonhemolytic Transfusion Reactions - p. 385 84. Chapter 62. Allergic Transfusion Reactions - p. 389 85. Chapter 63. Acute Hemolytic Transfusion Reactions - p. 393 86. Chapter 64. Delayed Hemolytic Transfusion Reactions - p. 397 87. Chapter 65. Transfusion-Associated Circulatory Overload - p. 401 88. Chapter 66. Transfusion-Related Acute Lung Injury - p. 405 89. Chapter 67. Septic Transfusion Reactions - p. 409 90. Chapter 68. Metabolic, Hypotensive, and Other Acute Reactions and Complications - p. 413 91. Chapter 69. Posttransfusion Purpura - p. 419 92. Chapter 70. Transfusion-Associated Graft-Versus-Host Disease - p. 423 93. Chapter 71. Transfusion-Related Immunomodulation - p. 429 94. Chapter 72. Iron Overload - p. 433 95. Chapter 73. Transfusion-Transmitted Diseases - p. 437 96. Section 12 - p. 452 97. Therapeutic Apheresis and Phlebotomy - p. 452 98. Chapter 74. Overview of Therapeutic Apheresis - p. 455 99. Chapter 75. Therapeutic Plasma Exchange - p. 469 100. Chapter 76. Therapeutic Erythrocytapheresis and Red Cell Exchange - p. 477 101. Chapter 77. Therapeutic Thrombocytapheresis - p. 481 102. Chapter 78. Therapeutic Leukocytapheresis and Adsorptive Cytapheresis - p. 483 103. Chapter 79. Extracorporeal Photopheresis - p. 487 104. Chapter 80. LDL Apheresis - p. 493 105. Chapter 81. Immunoadsorption - p. 497 106. Chapter 82. Therapeutic Phlebotomy - p. 501 107. Section 13 - p. 503 108. Cellular Therapy, Regenerative Medicine, and Tissue Banking - p. 503 109. Chapter 83. Overview of Cellular Therapy - p. 505 110. Chapter 84. Hematopoietic Progenitor Cell Products Derived From Bone Marrow and Peripheral Blood - p. 513 111. Chapter 85. Cord Blood Banking - p. 519 112. Chapter 86. Regenerative Medicine - p. 527 113. Chapter 87. T-Cell Immune Therapies - p. 533 114. Chapter 88. Adverse Events Associated With Hematopoietic Progenitor Cell Product Infusion - p. 537 115. Chapter 89. Quality and Regulatory Issues in Cellular Therapy - p. 543 116. Chapter 90. Tissue Banking in the Hospital Setting - p. 553 117. PART II: Hemostasis - p. 554 118. Chapter 91. Overview of the Coagulation System - p. 559 119. Section 14 - p. 564 120. Clinical Coagulation - p. 564 121. Chapter 92. Approach to the Pediatric Patient With a Bleeding Disorder - p. 565 122. Section 15 - p. 570 123. Neonatal Thrombocytopenia - p. 570 124. Chapter 93. Congenital Thrombocytopenia - p. 571 125. Chapter 94. Fetal and Neonatal Alloimmune Thrombocytopenia - p. 581 126. Chapter 95. Acquired Neonatal Thrombocytopenia - p. 589 127. Section 16 - p. 593 128. Inherited Platelet Function Disorders - p. 593 129. Chapter 96. Bernard–Soulier Syndrome and Other GPIb-IX-Related Receptor Defects - p. 595 130. Chapter 97. Glanzmann Thrombasthenia - p. 599 131. Chapter 98. Platelet Storage Granule Defects - p. 601 132. Chapter 99. Failure to Release and Aspirin-Like Defects - p. 605 133. Chapter 100. Other Platelet Abnormalities - p. 609 134. Section 17 - p. 610 135. Immune Thrombocytopenia - p. 610 136. Chapter 101. Acute (Childhood) Immune Thrombocytopenia - p. 613 137. Chapter 102. Chronic Immune Thrombocytopenia - p. 619 138. Chapter 103. Drug-Induced Thrombocytopenia - p. 623 139. Chapter 104. Heparin-Induced Thrombocytopenia - p. 627 140. Chapter 105. Autoimmune Lymphoproliferative Syndrome - p. 641 141. Section 18 - p. 644 142. Immune Mediated Coagulopathies - p. 644 143. Chapter 106. Hemolytic Uremic Syndrome - p. 645 144. Chapter 107. Thrombotic Thrombocytopenic Purpura - p. 649 145. Chapter 108. Antiphospholipid Syndrome - p. 655 146. Section 19 - p. 666 147. Congenital Bleeding Disorders - p. 666 148. Chapter 109. von Willebrand Disease - p. 669 149. Chapter 110. Hemophilia A - p. 677 150. Chapter 111. Hemophilia B - p. 685 151. Chapter 112. Factor XI Deficiency - p. 691 152. Chapter 113. Factor VII Deficiency - p. 695 153. Chapter 114. Factor II, Factor V, and Factor X Deficiencies - p. 699 154. Chapter 115. Congenital Disorders of Fibrinogen - p. 703 155. Factor XIII, α2-Antiplasmin, and Plasminogen Activator Inhibitor-1 Deficiencies - p. 707 156. Section 20 - p. 710 157. Acquired Bleeding Disorders - p. 710 158. Chapter 117. Bleeding Disorders in Pregnancy - p. 711 159. Chapter 118. Vascular Bleeding Disorders - p. 719 160. Chapter 119. Hemostasis in Liver Disease - p. 723 161. Chapter 120. Bleeding Risks With Vitamin K Deficiency - p. 729 162. Chapter 121. Bleeding Risks With Cardiac Disease - p. 735 163. Chapter 122. Bleeding Risks With Renal Disease - p. 739 164. Chapter 123. Bleeding Risks With Cancer - p. 743 165. Chapter 124. Disseminated Intravascular Coagulopathy - p. 749 166. Chapter 125. Coagulopathy in Sickle Cell Disease - p. 757 167. Chapter 126. Acquired Coagulation Factor Inhibitors - p. 761 168. Section 21 - p. 766 169. Laboratory Testing of Coagulation - p. 766 170. Chapter 127. Overview of Purposes of Hemostasis Testing and Common Sources of Error - p. 767 171. Section 22 - p. 772 172. Screening Tests - p. 772 173. Chapter 128. Prothrombin Time - p. 773 174. Chapter 129. Activated Partial Thromboplastin Time - p. 779 175. Section 23 - p. 781 176. Laboratory Assessment of Coagulation Disorders - p. 781 177. Chapter 130. Mixing Studies - p. 783 178. Chapter 131. Coagulation Factor Testing - p. 785 179. Chapter 132. Specific Factor Inhibitor Testing - p. 789 180. Chapter 133. Thrombin Time and Fibrinogen Evaluation - p. 793 181. Chapter 134. Laboratory Diagnosis of Inherited von Willebrand Disease - p. 799 182. Chapter 135. Laboratory Diagnosis of Acquired von Willebrand’s Syndrome - p. 807 183. Chapter 136. Laboratory Assessment of Treatment of von Willebrand Disease - p. 809 184. Chapter 137. Measurement of Platelet Count, Mean Platelet Volume, and Reticulated Platelets - p. 811 185. Chapter 138. Platelet Function Analyzer - p. 817 186. Chapter 139. Thromboelastography/Thromboelastometry - p. 819 187. Chapter 140. Platelet Aggregation Studies - p. 827 188. Chapter 141. Laboratory Diagnosis of Platelet Functional Defects - p. 833 189. Chapter 142. Confirmatory Testing for Diagnosis of Platelet Disorders - p. 841 190. Chapter 143. Antiplatelet Therapy Monitoring - p. 849 191. Chapter 144. Laboratory Evaluation of Factor XIII Deficiency - p. 855 192. Chapter 145. Fibrinolytic Testing - p. 861 193. Chapter 146. Laboratory Techniques in Fibrinolysis Testing - p. 865 194. Section 24 - p. 867 195. Tests for Hypercoagulable State - p. 867 196. Chapter 147. Laboratory Evaluation of Long-Term Thrombophilic Disorders - p. 869 197. Chapter 148. Thrombophilia Testing in the Pediatric Population - p. 875 198. Chapter 149. Antithrombin Testing - p. 881 199. Chapter 150. Protein C Deficiency Evaluation - p. 887 200. Chapter 151. Protein S Deficiency Evaluation - p. 893 201. Chapter 152. Testing for Activated Protein C Resistance - p. 899 202. Chapter 153. Molecular Testing for Factor V Leiden and Prothrombin Gene Mutations in Inherited Thrombophilia - p. 903 203. Chapter 154. Chronic Elevated Levels of Factor VIII and Other Coagulation Factors - p. 907 204. Chapter 155. Acquired Prothrombotic Conditions - p. 909 205. Chapter 156. Laboratory Evaluation of Heparin-Induced Thrombocytopenia - p. 913 206. Chapter 157. Laboratory Evaluation of Thrombotic Thrombocytopenic Purpura - p. 919 207. Chapter 158. Laboratory Diagnosis of Lupus Anticoagulant and Antiphospholipid Antibodies - p. 925 208. Section 25 - p. 931 209. Laboratory Support of Anticoagulation - p. 931 210. Chapter 159. Laboratory Monitoring for Heparins, Fondaparinux, Direct Thrombin Inhibitors, and Oral Anti-Xa Medications - p. 933 211. Chapter 160. Laboratory Support for Warfarin Monitoring - p. 939 212. Section 26 - p. 943 213. Emerging topics in hemostasis testing - p. 943 214. Chapter 161. Molecular Testing in Coagulation - p. 945 215. Chapter 162. Circulating Microparticles - p. 955 216. Chapter 163. Thrombin Generation Assays - p. 965 217. Chapter 164. Diagnostic Use of Venoms - p. 969 218. Abbreviations - p. 977 219. Index - p. 983
